<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="species">human</item><item key="factors"><item><item key="GSM905363"><item key="VARIATION">2.5 million copies of EGFRvIII receptor per cell</item></item></item><item><item key="GSM905363"><item key="VARIATION">2.5 million copies of EGFRvIII receptor per cell</item></item></item><item><item key="GSM90536"><item key="VARIATION">2 million copies of EGFRvIII receptor per cell</item></item></item><item><item key="GSM90536"><item key="VARIATION">2 million copies of EGFRvIII receptor per cell</item></item></item><item><item key="GSM905359"><item key="VARIATION">1.5 million copies of EGFRvIII receptor per cell</item></item></item><item><item key="GSM905359"><item key="VARIATION">1.5 million copies of EGFRvIII receptor per cell</item></item></item><item><item key="GSM905357"><item key="VARIATION">kinase dead EGFRvIII</item></item></item><item><item key="GSM905357"><item key="VARIATION">kinase dead EGFRvIII</item></item></item></item><item key="id">2610</item><item key="pop_total">0</item><item key="platform">4</item><item key="summary_wrapped">EGFRvIII is the most common deletion mutant of EGFR in human cancer and its levels are highly correlated with poor prognosis in GBM.  The...</item><item key="geo_gse_id">E-GEOD-36901</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">1</item><item key="sample_count">8</item><item key="tags"><item>cancer</item><item>cell</item><item>gbm</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_id_plat">E-GEOD-36901_A-AFFY-44</item><item key="slug">expression-data-from-u87mg-cells-expressing-egfrvi</item><item key="geo_gds_id"/><item key="name">Expression data from U87MG cells expressing EGFRvIII</item><item key="created">Jul.12, 2014</item><item key="summary">EGFRvIII is the most common deletion mutant of EGFR in human cancer and its levels are highly correlated with poor prognosis in GBM.  The deletion of exons 2-7 removes most of the extracellular ligand binding domain, so it is unable to bind EGF or other EGFR-binding ligands.  Nevertheless, the mutant receptor is constitutively phosphorylated, and is capable of activating downstream signaling pathways at a low level. To comprehensively identify the downstream signaling consequences of the EGFRvIII, we incorporated phosphoproteomic, transcription profiling and DNase-Seq data from U87MG glioblastoma cells expressing titrated levels of this mutant receptor. Total RNA were extracted from U87MG cells engineered to expressed different levels of EGFRvIII: medium (U87M; 1.5 million copies of EGFRvIII receptor per cell), high (U87H; 2 million copies per cell), super-high (U87SH; 2.5 million copies per cell), and kinase-dead EGFRvIII (U87DK; 2 million copies of kinase dead EGFRvIII per cell).  RNA was hybridized to Affymetrix microarrays.</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-36901</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-36901/samples/</item></data></biogps>
